Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

This study is testing a combination of ultra-precise, high-dose radiation (SBRT) with immune checkpoint inhibitor drugs in patients with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatment, to see if combining these approaches improves outcomes. **You may be eligible if...** - You are 18 or older (and under the study's upper age limit) - You have been diagnosed with stage IIIB or higher non-small cell lung cancer confirmed by biopsy - Your tumor is small enough (under 5 cm) to be suitable for SBRT radiation - You are eligible for immune checkpoint inhibitor therapy - You have given informed consent **You may NOT be eligible if...** - Your lung cancer is small cell or another type not covered by the study - Your tumor is too large for the required radiation technique - You have conditions that prevent safe use of immunotherapy Talk to your doctor to see if this trial is right for you.